Experts highlighted that robust pharmacopoeial frameworks are essential for maintaining the quality, safety and efficacy of medicines
The company allocated €56 million to research and development for next-generation line solutions
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Muted movement reflects consolidation phase as investors await earnings triggers
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The grant backed by Novartis to strengthen academia-industry collaboration across all seven NIPERs
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Subscribe To Our Newsletter & Stay Updated
